If the men only started going bald when they were 30 or 40, there was no difference in their risk of developing prostate cancer compared to the healthy group.
At present there is no hard evidence to show any benefit from screening the general population for prostate cancer. We need a way of identifying those men who are at high risk.
Further work should be done, both at the molecular level and with larger groups of men, to find the missing link between androgens, early balding and prostate cancer.